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Abstract
Background: Psychotherapy may be a useful intervention for inflammatory bowel disease (IBD)
patients. We systematically reviewed all randomized controlled trials that have been performed
in psychotherapy for inflammatory bowel disease patients.
Methods: Systematic searches were undertaken on 1 and 8 March, 2012 of studies of psychotherapy
for IBD.
Results: Eighteen studies (19 papers) were included in this review. Psychotherapy was found to
have minimal effect on measures of anxiety, depression, QOL and disease progression although
shows promise in reducing pain, fatigue, relapse rate and hospitalisation, and improving
medication adherence. It may also be cost effective.
Conclusions: The effects of psychotherapy on IBD is mixed: future studies should determine
whether patient screening or measuring different dependent variables improves outcomes and
whether particular psychotherapies are superior over others.
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1.1. Inflammatory bowel disease
Crohn's disease (CD), ulcerative colitis (UC), and indetermi-
nate colitis are chronic relapsing–remitting inflammatory
conditions of the intestines which are collectively referred to
as inflammatory bowel disease (IBD).1 The commonest
symptoms are bloody stools, diarrhoea, fatigue, abdominal
pain, loss of appetite, weight loss and fever.2 Extra-intestinal
symptoms also often occur,3–6 with anaemia being the most
common.7 IBD has traditionally been thought of as a diseaseof the Western world,8–10 although is increasing in prevalence
in Asia11,12 and Latin America.13,14 The aetiology of IBD
remains elusive and complex, although it is thought to relate
to genetic,6,15 environmental,16,17 and immunological6 fac-
tors. Although not curable, a wide range of treatments are
available: medical,18,19 surgical,1,20 and dietary manipula-
tion21,22 are options in the management of IBD.
1.2. Psychotherapy for IBD
The role of psychotherapy in the treatment of IBD is
uncertain. A range of studies have reported the profound
937Psychotherapy for inflammatory bowel disease: A review and updateimpact of the disease on the psychological wellbeing
of patients.23–27 Despite this recognised association,
psychiatric comorbidities are often underdiagnosed and
undertreated.28 Certain psychological characteristics, such as
neurotic personality,29 stress,30,31 or coping styles32–41
may influence psychological or disease-related outcomes.
In addition, behaviours such as good medication adherence
or sustained smoking cessation (in CD) are important in
preventing disease flares.42,43 Therefore, psychotherapies
targeting stress management, enhancing coping strategies,
and decreasing detrimental behaviours (e.g. medical noncom-
pliance) may improve psychological wellbeing and disease
course of IBD patients.
Six reviews concerning the role of psychotherapy for IBD
have been published since 2006.26,44–49 Four of these were
systematic reviews,44,47–49 including a Cochrane review.48
The Cochrane review, using stringent inclusion criteria,
concluded that there is no evidence favouring psychotherapy
in adults with IBD but the evidence is slightly better in
adolescents. The Cochrane and other reviews have also
argued that certain patients are more likely to benefit from
therapy than others, namely those who both require (i.e. are
suffering from psychological distress) and want it.45,47,48 A
number of papers in this area have been published since.1.3. Aims
Our aim is to systematically review and update the literature
regarding psychological interventions for IBD. The Cochrane
review and subsequent publications are considered for this
review. Papers from the “excluded studies” section of the
Cochrane review are also reported if they were considered
relevant.2. Methods
2.1. Criteria for including studies
2.1.1. Inclusion Criteria
Articles were included if they (a) involved IBD patients,
(b) performed psychotherapy (i.e. not just education or
self-management), (c) had control groups, (d) were published
in English (e) involved more than one session of psychother-
apy, (f) used quantitative psychological or disease-related
outcomes, and (g) were published after 1980.
2.1.2. Exclusion criteria
Abstracts50–54 and studies which were incomplete or had
inadequate reporting of results55,56 were excluded.2.2. Search strategy
The Cochrane review was the last systematic review and
searched for papers until April 2010.48 All papers from the
“included studies” and “excluded studies” sections were
considered. Databases were also searched for studies that
have been performed since this time. Searches were
performed on the databases on 1 and 8 March, 2012, with
limits to the years of 2010–2012.2.2.1. Psycinfo
(exp psychotherapy or exp cognitive therapy) AND (exp
ulcerative colitis or exp colon disorders or inflammatory
bowel disease or Crohn's disease).2.2.2. Embase
(exp psychotherapy) AND (exp colitis or exp ulcerative colitis
or exp Crohn's disease).2.2.3. Medline
(exp inflammatory bowel disease) AND (exp psychotherapy).2.3. Study selection
All studies from the Cochrane review were re-examined
including the “excluded studies” section. Three studies from
the “excluded studies” section were included because they
met our inclusion criteria57–59 and eight studies (entailing
nine papers) were included from the “included studies”
section because they involved stress management or psycho-
therapy.60–68 Ten studies included in the Cochrane review
were excluded because they comprised education only, one
study was excluded because it was in abstract form only,54
one study was excluded because it was not published in
English,69 and one study was excluded due to inadequate
reporting of results.56 Therefore, eleven studies in total were
included from the Cochrane review (eight from the “included”
section and three from the “excluded” section).
Moreover, the databases above were searched for addi-
tional studies. Overall, the psycinfo search uncovered 23
results from which one article was included70; the embase
search uncovered 60 results from which seven articles were
included55,70–75; and the medline search uncovered 12
results from which two articles were included.71,72 Three
of the articles were found in more than two databases70,71
and so seven studies overall were included. The reference
lists of each paper were searched. In total, eighteen
studies (entailing nineteen papers) were included in this
review.55,57–68,70–752.4. Data extraction
The data extracted from the papers were the author, year,
country, sample size (n), whether there was screening of
psychological distress, control group, treatment group, treat-
ment duration, outcome variables, blinding procedures,
follow-up length, dropout percentage, main findings, topics
covered, who delivered the treatment, and whether the
treatment was standardized.3. Results
3.1. Papers included in review
Eight studies included in Cochrane review, three studies
excluded from the Cochrane review, and seven studies
published after the Cochrane review were included in this
review (see Tables 1 and 2).
Table 1 Controlled psychotherapy trials for inflammatory bowel disease patients.
First author, year, country, & citation na Control group (na) Treatment groups (na) Screening psychological
distress?
Number of sessions Outcome variables
Diaz Sibaja, 2007, Spain57 57 CDc=34UCd=23 WLCe (24) Group therapy (33) Excluded those with
“severe psycho-pathology”
10 weekly 2 hour group
sessions
Anxiety & depression
Shaw, 1987, USAf58 40 UCd ACg (20) PRh (20) No 6 weekly 75 minute
sessions
Pain measures &
medication use
Wahed, 2010, UKj59 48 UCd=26 CDc=11 Matched controls
(no counselling)
(24)
CBTk & SFT,l continuous
psychological
support (24)
Cases referred for
IBDm-related stress (14),
work problems (3),
surgery concerns (5),
& bereavement (2)
Unlimited sessions,
6 (1–13) 1-hour sessions
Relapses, outpatient
attendances, admissions,
steroid courses, use of
other IBDm medication
Boye, 2011, USAf 71 114 CDc=56 UCd=58 TAUn (23 UC,d
34 CDc)
SMo therapy
(35 UCd & 22 CDc)
Yes: high psychological
distress
3×3 hour group & 6–9 individual
sessions (time not specified)
Disease course, relapse rates,
& QOLp
Vogelaar, 2011, Norway74 29 CDc TAUn (N=12) PSTq (N=9) or SFTl
(N=8)
High fatigue & clinical
remission recruited
PSTq (10 sessions), SFTl
(5 sessions);
both over 3 months;
time per session
not specified
Fatigue, QOL,p & medical
costs
Hommel, 2012, USAf72 40 CDd=30 UCd=7 ICr=3 TAUn (20) Family-based group
BTs (20)
Adolescents 4 sessions (60–90 min)—
6 weeks
Medication adherence
(pill counts/electronic
monitoring)
Hommel, 2011, USAf73 14 (CDc=11 UCd=4) WLCu (7) Individually tailored
BTs (7)
Adolescents 4 sessions (60–75 min) Medication adherence
Keefer, 2012, USAf75 28 CDc TAUn (n=12) PMv based on CBTk
(n=16)
Patients without
psychiatric disorder
6 session (60 min)—6
weeks
QOL,p medication adherence,
perceived stress, self-efficacy
Keefer, 2011, USAf70 36 (CDc` =5 UCd=31) UCd ACg & CDc
WLCe (N=12)
HTw for UCd; CBTk
for CDc (24)
No 7 sessions (45-60 min) Flare history
Keefer, 2011, USAf55 36 UCd ACg (17) HTw (19) No 7 sessions (45 min) HTw acceptability,
self-efficacy, perceived
health competence & stress,
concerns, adherence,
& QOLp
Garcia-Vega, 2004,
Spain60
45 CDc TAUn (n=15) Therapist delivered
(n=15) &
self-directed SMo
(n=15)
No For SMo: 8 sessions. For
self-directed SMo:
10 sessions; time per
session not
specified for either
“symptom reduction score”
via symptom diary
Larsson, 2003, Sweden61 49 (CDc=26, UCd=2) WLCe (17) GEIy with SM (26) Yes: HADSz≥8 8×2–3 hour sessions Anxiety, QOL`, & participant
satisfaction.
Smith, 2002, UKj62 100 (CDc=50, UCc=50) TAUn (50) Nurse-led counselling (50) No Mean 3.25 consultations
over 1 year
QOL,p coping, depression, anxiety,
& disease activity
Grootenhuis, 2009,
Netherlands63
40 IBDm TAUn (18) PEcc group intervention (22) No 6 sessions (time not specified) Coping styles, feelings of
competence, & QOLp
Szigethy, 2007, USAf64 41 (CDc=29,UCd=12) TAUn (19) CBTk (22) 11–17 years old: mild-moderate
subsyndromal depression
9–11×1 hour sessions. CDIdd (child/parent report),
K-SADS,ee CGAS,ff
& PCSC.gg
Langhorst, 2007, Germany65 60 UCd TAUn (30) SM,o PE,cc & self-care
strategies (30)
No 60 hours over period 10 weeks QOL,p hospitalizations,
distress, & clinical disease
activity
Jantschek, 1998, Germany66 108 CDc TAUn (31) PThh & relaxation (53) No ≥20 h over 1 year,
variable intervals/session times
Life satisfaction; depression
anxiety, hospital days, days
off work, & ranking of
disease course over
1–2 years
Deter, 2007, Germany68 69ii CDc TAUn (37) PThh & relaxation (71) No PThh (20 h) & relaxation
(10 sessions).
Hospital & sick leave days
Oliveira, 2007, Brazil67 39 (not specified) No SSjj (12) SSjj (27) No Once per month, up to 2 years IBDQaa & SF-36bb
938
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Table 1 (continued)
First author, year, country, & citation Blinding of assessors? Follow-up Included in, excluded from,
or after Cochrane review
Dropout (%) Main findingsb
Diaz Sibaja, 2007, Spain57 Not reported 12 months Excluded because uncontrolled follow-up ~50% after 12-month
follow-up
Improvement in anxiety & depression which were sustained
at 3, 6, & 12 months
Shaw, 1987, USAf58 Not reported 6 weeks Excluded because outcome not
relevant to review question
Not reported Compared to AC,g PRh subjects used fewer words to describe
pain, reported less pain intensity & frequency, rated greater
pain relief, reported less pain-distress, & used fewer AIi drugs.
Wahed, 2010, UKj59 Not reported 1 year Excluded because of the use of
historical controls
0% Fewer relapses & outpatient attendances than in the previous
year. Steroid & other IBDm medication use decreased in
treatment group. No such changes in control group. No change
in hospital admissions in either group. In 20 patients who
attended N1 session, counselling helped solve stress-related
difficulties.
Boye, 2011, USAf 71 Yes 18 months Published subsequent to Cochrane review 19% of UCd & 13%
of CD.c
Intervention did not improve disease or reduce relapse but
improved QOLp in UC.d
Vogelaar, 2011, Norway74 Not reported 3 months Published subsequent to Cochrane review 44% PST,q 12.5%
SFT,l & 8.3% TAUn
Compared with TAUn (45.5%), SFTl (85.7%) and PSTq (60%) had
improved fatigue. Insignificant increase in QOLp for PSTq &
SFT.l Lower medical costs in SFTl (57.1%,) compared with TAUl
(45.5%) & PSTq (20%).
Hommel, 2012, USAf72 No 1 week Published subsequent to Cochrane review 0% Improved mesalamine adherence (25%) improvement treatment
group vs. 1% increase in the TAU,n but not for 6-MP.t
Hommel, 2011, USAf73 No 1 week Published subsequent to Cochrane review 0% Greater thiopurine adherence compared with controls, & a
nonsignificant increase in mesalamine adherence
Keefer, 2012, USAf75 No Immediately after
intervention
Published subsequent to Cochrane review Not specified No improvement in drug adherence, emotional or social functioning.
PMv improved bowel, systemic symptoms, perceived stress,
& self-efficacy.
Keefer, 2011, USAf70 2 blinded research
assistants
12 months Published subsequent to Cochrane review 0% 12 month disease flares fewer in treatment (57%) than control
(14%) group. The decline in “flare odds” was about 2 times
greater in treatment vs controls (ORx=0.52).
Keefer, 2011, USAf55 Therapist blinded
to outcome
20 weeks Published subsequent to Cochrane review 12% over 6 months The HTw group reported more improvement than the ACg group
in physical QOLp at both post-treatment & 20 weeks.
Garcia-Vega, 2004,
Spain60
Blinded outcome
assessment
12 months Included 0% SMo led to decrease in tiredness, constipation, abdominal pain &
distended abdomen. Self-directed SMo patients had decreases in
tiredness & abdominal pain. No changes were observed in TAU.n
Similar results obtained in 12 month follow-up
Larsson, 2003, Sweden61 No 6 months Included 46.9% No change of anxiety at 6-month follow-up for those in GEIy & no
changes over time for bowel & systemic symptoms, emotional &
social functioning of IBDQaa or generic QOLp (SF-36bb).
Smith, 2002, UKj62 No 12 months Included 0% Counselling had no effect on QOL,p coping, depression, anxiety, &
disease activity
Grootenhuis, 2009,
Netherlands63
No 6–8 months Included 20% PE had a positive effect on: coping (predictive control) feelings of
competence (global self-worth & physical appearance), & QOLp
(body image).
Szigethy, 2007, USAf64 Yes 3 months Included 7.3% CBTk group showed greater improvement in CDIdd (child/parent
report), CGAS,ff & PCSCgg post-treatment than the TAUn group.
Langhorst, 2007, Germany65 No 12 months Included 6.7% At 3 months, the treatment group showed greater improvements
in SF-36bb physical function & greater reduction in anxiety.
Jantschek, 1998, Germany66 No 2 years Included 22.2-25% The main analysis, which was based on subranking by number,
duration, and severity of relapses, failed to show significant
differences between the two groups (P=0.125). No significant
differences between the TAUn and PThh groups in terms of
episode-free courses (23% v 30%, pN0.05); surgery (29% v 17%,
pN0.05); overall disease course; psychosocial status; depression;
anxiety; QOLp
Deter, 2007, Germany68 Yes 1 year Included 39.4% in PThh &
29.7% in TAU.n
Treatment group had a significant reduction in hospital days
& sick leave days.
Oliveira, 2007, Brazil67 No Up to 18 months Included 28.2% SSjj had a positive impact on the social & emotional aspects of
QOL.p 939
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940 A.M. McCombie et al.3.2. Research designs
3.2.1. Sample size
A total of 924 study participants were analysed in eighteen
studies (entailing nineteen papers).3.2.2. Screening
Three studies included those who scored high on psycholog-
ical distress,71 anxiety scores,61 and mild-moderate sub-
syndromal depression.64 Twelve studies did not screen for
psychological status.55,58,60,62,63,65–68,70,72–74 One study
excluded patients with “severe psychopathology”57 and ano-
ther study excluded those with a psychiatric disorder.75 One
study had patients referred for counselling for various stress-
related reasons.3.2.3. Control groups
Eleven studies used treatment as usual (TAU) as the control
group,60,62–68,71,72,74,75 three studies waitlist control (WLC) as
the control group,57,61,73 two studies used active attention
control as the control group55,58 one study retrospectively
matched patients who did not receive counselling to those who
did receive counselling,59 and one study had a mix of active
attention control and WLC patients.703.2.4. Treatment
Four studies used group based programs,57,61,63,72 two
studies used hypnotherapy,55,70 three used cognitive behav-
ioural approaches,59,64,75 two studies used relaxation,58,66,68
three studies used stress management techniques,60,65,71 one
study used social support,67 one study used an individually
tailored behavioural treatment,73 one study used nurse-ledNotes to Table 1:
a n=sample size.
b All main findings reported were significant (i.e. pb0.01 or 0.05) unless explicitly stated
c CD=Crohn's disease.
d UC=ulcerative colitis.
e WLC=waitlist control.
f USA=United States of America.
g AC=Attention control.
h PR=progressive relaxation.
i AI=anti-inflammatory.
j UK=United Kingdom.
k CBT=cognitive behavioural therapy.
l SFT=solution focused therapy.
m BT=behavioural treatment.
n IBD=inflammatory bowel disease.
o TAU=treatment as usual.
p SM=stress management.
q QOL=quality of life.
r PST=problem solving therapy.
s IC=indeterminate colitis.
t 6-MP=mercaptopurine.
u WLC=waitlist control.
v PM=project management.
w HT=hypnotherapy.x OR=odds ration.y GEI=group educational intervention.
z HADS=hospital anxiety and depression scale.
aa IBDQ=inflammatory bowel disease questionnaire.
bb SF-36=Short form 36.
cc PE=psychoeducation.
dd CDI=Children's depression inventory.
ee K-SADS=Schedule for Affective Disorders and Schizophrenia for School-Age Children.
ff CGAS=Children's Global Assessment Scale.
gg PCSC=Perceived Control Scale for Children.
hh PT=psychotherapy.
ii Please note that this sample was derived from the same sample as the Jantschek et al. (
jj SS=Social support.counselling,62 and one study had problem solving therapy and
solution focused therapy as interventions.74
3.2.5. Treatment durations
Treatment duration varied from 3 sessions to a 3 month
program.
3.2.6. Outcomes
The outcomes measured were depression,57,62,64,66 anxi-
ety,57,61,62,65,66 quality of life (QOL),55,60–63,65,67,74,75 relapse
frequency,59,66,70,71 hospitalizations,59,65,66,68 sick-leave
days,68 symptoms,60 fatigue,74 medication adherence,72,73
and pain measures.58,60
3.2.7. Blinding procedures
Six studies reported some form of blinding.55,60,64,68,70,71
3.2.8. Follow-up length
Follow-up ranged from no follow-up to 5 years.
3.2.9. Dropout percentages
Dropout rates ranged from 0% at post-intervention to 50%.
3.2.10. Treatment standardization
Six studies did not mention standardization of treat-
ment,58,61,63,67,72,73 nine studies used some form of standard-
ization of treatment,55,57,62,64,66,68,70,71,75 and four had the
same therapist deliver the therapy to all patients59,60,65,74
(Table 2).
3.2.11. Therapists
Four studies did not specify who delivered the thera-
py,57,58,65,67 nine studies used a psychologist or psychother-
apist,55,60,63,66,68,70,72–75 one used a counsellor,59 one usedotherwise.
1998) study.
Table 2 Topics covered, who delivered the treatment, and whether the treatment was standardized.
Citation Topics covered Who delivered the treatment? Was treatment standardized, was a
manual used, or did the same
counsellor deliver treatment to all
patients?
57 IBD a information, coping, problem
solving, progressive muscle relaxation,
& social skills
“therapists” unspecified Yes-used a manual
58 Progressive relaxation Not specified Not mentioned
59 CBT b & SFT c (no further detail given) Counsellor Same counsellor delivered treatment
71 Stress, coping, living with a chronic
illness, structured problem solving,
relaxation, identifying stressors,
modifying dysfunctional cognition,
improving stress management,
self-esteem, perception of control
Clinical psychologist, psychiatrist,
psychiatric nurse, & physiotherapist
Meetings were held to ensure
treatment was delivered consistently
across therapists
74 PST d & SFT c (no further detail given) Psychotherapist Same person delivered to all
72 IBD a education, medication
adherence, behaviour modification,
family functioning
Doctoral level clinical psychologists
or post-doctoral fellows
Not mentioned
73 IBD education, medication adherence,
behaviour modification, family
functioning
Doctoral level clinical psychologists
or post-doctoral fellows
Not mentioned
75 Project management, symptom
monitoring, time management, sleep
hygiene, planning dietary & exercise
goals, risk management & relapse
prevention
Health psychologist Yes
70 Hypnosis, stress management, disease/
medication knowledge, coping &
medication adherence
Doctoral level health psychologists Yes
55 Trained hypnotherapists Doctoral level health psychologists Yes
60 Stress, tension, coping skills,
progressive muscle relaxation, personal
planning skills, autogenic training
Psychologist Same psychologist for all
61 General medical information about
IBD a & its pharmacological & surgical
treatment, information about nutrition
& diet, stress & stress management, as
well as how to adapt & cope with
chronic disease in general
A gastroenterologist, surgeon,
psychiatrist, physiotherapist, dietician,
specialist nurse of stoma care, medical
social worker & several members of the
patient organization provided the
various kinds of information.
Not mentioned
62 Appropriate coping mechanisms & the
use of relaxation techniques
Nurse Yes
63 Coping strategies such as information
seeking, relaxation techniques,
proactive behaviour with peers, &
positive thinking to increase self-worth
& social–emotional functioning
Two psychologists Not mentioned
64 IBD a education, relaxation,
self-hypnosis, showing positive self,
activity planning, practicing talents,
negative cognitions, coping skills, &
predicting future problems
Two child psychiatrists, two child
psychologists, & two clinical social
workers
Yes: PASCET-PI e manual
65 Stress reduction & stress management,
combined with a recommendation for a
Mediterranean-type diet containing
whole grain foods. Regular exercise &
increased daily activity were strongly
recommended, & each day of the pro-
gram included 30 min of light exercise.
“therapist” unspecified Both interventions were conducted by
the same therapist.
(continued on next page)
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Table 2 (continued)
Citation Topics covered Who delivered the treatment? Was treatment standardized, was a
manual used, or did the same
counsellor deliver treatment to all
patients?
66 The aim of verbal psychotherapy was to
provide health education &
health-promoting behaviours, to give
patients greater responsibility & con-
trol in treatment, & to improve coping
skills & adjustment to the disease.
Psychotherapy was applied in accor-
dance with the principles of psychody-
namic psychotherapy.
Therapists were experienced
postgraduate physicians or
psychologists trained in psychodynamic
treatment.
On the basis of tape-monitored ses-
sions, every patient's third & last
session were controlled with regard to
consistency of psychotherapy by a
blinded expert rating in a referral
centre.
68 Basic short-term psychodynamic psy-
chotherapy (20 h) & a relaxation
treatment program (10 autogenic
training sessions)
Not specified Although no manual was used, the
psychotherapy provided was based on
the principles of psychodynamic
psychotherapy & was standardized
within the study centres.
67 Support meetings, held on a monthly
basis, aimed at facilitating &
stimulating discussion about the
problems & concerns of patients with
IBD a (ostomies, surgery, relation to
cancer, diet, uncertainties about
outcome, drug side effects). In
addition, those meetings provided
information on the rights of patients
with chronic diseases & debated issues
related to IBD a that could be of
interest to the patients.
Not specified Not mentioned
a IBD=inflammatory bowel disease.
b CBT=cognitive behavioural therapy.
c SFT=solution focused therapy.
d PST=problem solving therapy.
e PASCET-PI=Primary and Secondary Control Enhancement Therapy-Physical Illness.
942 A.M. McCombie et al.a nurse,62 and three used a combination of health pro-
fessionals61,64,71 (Table 2).
3.3. Main findings
3.3.1. Effect of psychotherapy on anxiety
Five studies had anxiety as an outcome variable.57,61,62,65,66
Two of these reported psychotherapy reduced anxiety57,65
while three reported no effect.61,62,66 Of note was that
Larsson et al. found no effect of psychotherapy despite
screening and only including patients with high anxiety scores
(Hospital Anxiety and Depression Scale score greater than 8)
thus eliminating ‘floor effects’.61
3.3.2. Effect of psychotherapy on depression
Four studies had depression as an outcome variable57,62,64,66
with two reporting a positive effect of psychotherapy on
depression57,64 and two reporting no effect.62,66
3.3.3. Effect of psychotherapy on quality of life
Nine studies included QOL as an outcome mea-
sure.55,60–63,65,67,74,75 Three studies found psychotherapy
to have a positive effect on QOL,55,63,67 two studies foundpsychotherapy to have no effect,62,66 three studies had mixed
results,65,71,75 and one study had trends to a positive effect
but without an adequate sample size to detect statistical
significance.743.3.4. Effect of psychotherapy on general symptoms
One study found a cognitive behavioural approach improved
bowel and systemic symptoms.75 A further study showed
that those who received stress management had greater
reductions in constipation, and distended abdomen than
TAU patients.60 Conversely, two studies showed psycho-
therapy to have no effect on disease activity62,65 although one
of these studies only included those in clinical remission
or with low disease activity thus creating possible “floor
effects”.62,653.3.5. Effect of psychotherapy on pain
Both studies on pain both reported a positive effect of
psychotherapy. A small trial (n=40) for UC patients found
that progressive relaxation led to less pain intensity, frequen-
cy, and distress, as well as use of fewer anti-inflammatory
drugs.58 A study found that those who received stress
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TAU patients.60
3.3.6. Effect of psychotherapy on fatigue
Both studies on fatigue found psychotherapy to have
positive effect. One study found an improvement in fatigue
in treatments versus controls with 85.7% of solution focused
therapy, 60% of problem solving therapy, and 45.5% of TAU
allocated patients having an improvement in fatigue74 although
these differences were not significant due to a small sample
size. Another study showed stress management to significantly
reduce tiredness as compared to TAU.60
3.3.7. Effect of psychotherapy on relapse frequency and
number of hospitalizations
One study which retrospectively compared patients who
received psychological counselling to matched controls
reported that those who received counselling had fewer
relapses and outpatient visits than in the year before coun-
selling, while steroid use & relapse-related use of other IBD
medications also decreased. These changes were not observed
in the controls.59 Hypnotherapy was found to significantly
reduce relapse of UC in another study.55 Trends to a
positive outcome were found in a study comparing psycho-
therapy with TAU but not significantly.66 Conversely stress
management was not found to reduce relapse in one study71
or reduce hospitalizations in another.65 One study reported
that psychotherapy and relaxation led to a greater reduction
in sick leave days and days spent in hospital compared to
TAU.68
3.3.8. Effect of psychotherapy on medication adherence
Two studies by Hommel et al. found that (a) group behavioural
treatment led to improved mesalamine treatment adher-
ence72 and (b) individually tailored behavioural treatment
led to improved 6-MP and azathioprine adherence.73
However, a cognitive behavioural approach failed to lead
to improved medication adherence in another study of 28
CD patients.75
3.3.9. Cost effectiveness
One British multicentre study of patient self-management
found an average decrease in direct health costs of £148 per
patient year.76 Recently, a small study of 29 CD patients
found that solution focused therapy was more cost effective
than problem solving therapy and TAU, with 57.1% of solution
focused therapy patients having a decrease in medical costs
3 months after finishing therapy compared to 45.5% of TAU
and 20% of problem solving therapy.74However, the small
sample size meant that these results were not statistically
significant.
3.3.10. Comparing therapies with each other
The Cochrane review argued that there is a lack of evidence
regarding which therapy is best.48 One recent study did
compare problem solving therapy with solution focused
therapy and found that solution focused therapy had a
greater effect than problem solving therapy with reduced
fatigue (85.7% versus 60%, pN0.05) as well as a lower
dropout rate (12.5% versus 44%, pN0.05), although the small
sample size meant that these differences were not signifi-
cant.74 Garcia-Vega et al. compared therapist deliveredstress management with self-directed stress management
and found that self-directed stress management was the
best intervention over time despite the lack of therapist
contact and therapist delivered stress management having
the greatest effects post intervention.60
3.3.11. Effect of type of therapist on outcomes
All studies with unspecified therapist reported at least
some positive effects57,58,65,67 while just one out of three
studies which used a mix of health professionals61 showed
some positive effects. The one study to have used a nurse
showed no effects62 whereas the one study to have used a
counsellor showed treatment to reduce relapses and out-
patient attendances.59 All studies to have used a psy-
chologist or psychotherapist showed at least some effects
of treatment.55,60,63,66,68,70,72–75
4. Discussion
The evidence for whether psychotherapy improves anxiety,
depression, QOL, symptoms, or disease course is mixed. It
may be reasonable to support the Cochrane review in stating
that there is no evidence favouring psychotherapy using
these outcome measures.48 However, psychotherapy as an
intervention for pain, fatigue, and medication adherence
has shown early promise. All studies which used a psychol-
ogist, psychotherapist, counsellor, or unspecified therapist
reported significant effects in terms of at least one outcome
variable while the one study to have used nurse led therapy
showed no effects of psychotherapy. Further studies are
needed to replicate these findings. Psychotherapy may also
be cost effective. To date, little is known about the cost-
effectiveness of psychotherapy for IBD patients and it is still
unknown which patients benefit most from it. Finally, data
directly comparing treatment regiments (e.g. cognitive
behavioural therapy [CBT] versus hypnotherapy) are lacking.
4.1. Implications and future directions
While the evidence for psychotherapy as an adjunct therapy
for IBD patients is mixed, we suggest that there are three
ways of improving studies in the future.
4.1.1. Targeting specific patients
There may be advantages in targeting specific patients,
including adolescents48 and, due to “floor effects”, those
with significant psychiatric comorbidity for psychothera-
py.26,47,48 Psychological screening at baseline is rare in IBD
studies.61,64
Some people may be more suited to psychotherapy. For
example, in the context of depression, better responses have
been reported in those younger and less socially impaired77
while worse outcomes occurred in those with more episodes
of depression, high baseline depression, worse chronicity of
depression, younger age of onset, co-morbid axis I disorders,
and single marital status.78–82
Studies have rarely included patients with active disease
at baseline.44 Goodhand et al.44 argue that more patients
with active disease should be recruited in future studies.
This may be difficult because sicker patients may be less
willing and able to attend psychotherapy sessions when their
944 A.M. McCombie et al.disease is active and assessment may be confounded by the
use of concomitant medical therapies.
Screening instruments have been developed to identify
whether patients would benefit from therapy. One tool is the
Assessment of the Demand for Additional Psychological
Treatment (ADAPT). ADAPT measures “need for psychosomat-
ic support” (synonymous with “need for physicians support”)
and “need for psychotherapy”. When 302 IBD patients were
compared to 109 rheumatoid arthritis (RA) patients, IBD
patients expressed a greater need for a psychological
intervention than RA patients (31% versus 13%, pb0.001).83
Among IBD patients, the need for physician support was
predicted by worries and concerns about IBD, while the need
for psychotherapy was associated with worries and concerns
about IBD, anxiety, impaired social functioning, and short
disease duration. This shows that the need for psychotherapy
is there for approximately a third of IBD patients but this need
is not being met. Qualitative research could determine what
exactly IBD patients would like to gain from psychotherapy.
4.1.2. Matching treatments with patients
Determining which patients will respond to a specific
psychological treatment is complex. The requirements of
individual patients who may benefit from psychotherapy
vary significantly; some will have mood disorders indepen-
dent of IBD whereas others have psychological problems
caused by the disease itself (i.e., adjustment disorder).44
The stressors among those with adjustment disorder vary
considerably: concerns about employability, the increased
risk of cancer, future surgery, future exacerbations, embar-
rassment, and side effects of medications are just some of
the stressors that IBD patients face. In addition, some
patients may have cognitive distortions surrounding their
disease64 leading to poorer psychological wellbeing, while
others may have behavioural problems directly impacting
their prognosis, such as smoking84 or poor medication
adherence.85,86 Therefore, it is important that therapy is
tailored appropriately for the individual.
If the source of their psychological distress is the severity
of the symptoms of the IBD itself, conventional psychological
interventions may be unable to help these patients who may
be more responsive to pain management and hypnotherapy.
Conversely, those with stressors outside the direct realm of
the disease itself may be more responsive to conventional
psychological interventions, especially when their disease is
inactive. To date, only two studies have compared one
psychotherapy with another60,74; future studies should
compare therapies and determine whether individualising
psychotherapies for each patient is advantageous.
4.1.3. Measuring different dependent variables
Different outcomemeasures may lead to different conclusions
regarding which patients benefit from psychotherapy. For
example, Deter et al.68 reported that psychotherapy and
relaxation led to a greater reduction in sick leave days and
days spent in hospital compared to controls despite their
patients having few psychological problems at baseline. They
estimated that the benefits of psychotherapy (i.e., less sick
days and days in hospital) outweighed the costs (i.e., cost of
psychotherapy sessions) by a ratio of 6.5 to 1. Perhaps
psychological interventions improve the ability of the patient
to cope with IBD regardless of the psychological status of thepatient. Researchers need to not only investigate whether IBD
patients are feeling subjectively better due to their treat-
ment, but also whether the intervention has reduced illness
costs.
Hommel et al. found that behavioural interventions im-
proved medication adherence in adolescents72; this may not
necessarily mean that the mental health of these adolescents is
improved, but implies that disease course is improved through
better medication compliance. Future studies should address
behavioural issues that can improve disease course, such as
medication adherence.
Psychological treatments show potential for a wide range
of illness in terms of cost-effectiveness (including heart
disease, hypertension, diabetes, cancer, and chronic pain.87)
It is now time to consistently incorporate such cost–benefit
analyses into IBD psychotherapy studies. Only two studies have
incorporated cost effectiveness analyses and both reported a
significant cost saving.74,76
Finally, the phenotypic variability observed in IBD has
implications for measuring demonstrable effects of interven-
tions including psychotherapy. Such variability has often
meant that clinical trials of new drugs need to be better
powered than studies in comparable inflammatory diseases
such as RA and ankylosing spondylitis. Furthermore, the
overlap with functional diseases such as irritable bowel syn-
drome (IBS), which is present in many with IBD in remission,88
may also be a confounder.4.1.4. Is psychotherapy ineffective for IBD?
Alternatively, perhaps IBD is simply less amenable to change
via psychological interventions than some other diseases
are, such as chronic pain,89 chronic fatigue syndrome,90 or
diabetes.91 Cochrane reviews have also found less than
satisfactory results for epilepsy,92 tinnitus,93 depression
after stroke,94 or metastatic breast cancer.95 Furthermore, a
Cochrane review of IBS found psychotherapy to be superior to
TAU but not to placebo (i.e. sham psychotherapy)96; given
IBS's stronger psychosomatic underpinning compared with
IBD,97 it may be less likely that IBD will be amenable to
change via psychotherapy.
Nevertheless, there is consistent evidence that psycho-
logical stress exacerbates IBD,44 and so it seems plausible
that interventions aimed at reducing stress should lead to
better patient outcomes.
If psychotherapy does not help IBD patients, alternative
means of treating mood disorders in IBD patients should be
found. Antidepressant therapy has shown early prom-
ise.44,98,99 A review in 2009 reported preliminary evidence
of effectiveness of antidepressants in three animal RCTs and
called for human RCTs to be performed.100 One such study
found that imipramine improved both mood and disease
activity,101 albeit with methodological limitations.44 A small
retrospective case–control study found that IBD patients
who were put on antidepressants were less likely to relapse,
had lower steroid use, and fewer endoscopies than their
matched control group counterparts.102 As to whether the
addition of antidepressant therapy will be acceptable to IBD
patients who are often already heavily medicated is ques-
tionable. Nevertheless, given the preliminary promise for
antidepressants in treating IBD patients with comorbid mood
disorders, an RCT would be beneficial.
945Psychotherapy for inflammatory bowel disease: A review and updateHowever, antidepressant therapy can lead to relapse
once discontinued103 and psychotherapy may have a role to
play in relapse prevention (of depression).104 Despite com-
bination therapy (i.e. antidepressants with psychotherapy)
showing promise for treating psychiatric illness,104–106 no
studies comparing combination with antidepressant therapy
or psychotherapy have been performed in IBD patients.
Therefore, future studies should compare psychotherapy
versus antidepressant therapy versus combination therapy in
IBD patients.
Finally, it is possible that psychotherapy has a modest
effect but without a sufficient effect size to indicate
cost-effectiveness. If this is the case, computerised cognitive
behavioural therapy (CCBT) is a cheaper alternative96,107 and
may be as effective as conventional CBT.108,109 Moreover, the
low costs mean it can be offered to more patients. CCBT has
had particular success in IBS109–113 and chronic pain114–118
patients and studies are underway measuring its suitability
and effectiveness for IBD patients.119,120
5. Conclusions
Psychotherapy for IBD has minimal effect on measures of
anxiety, depression, QOL and disease progression. It shows
promise in reducing pain, reducing fatigue, reducing relapse
and hospitalisation, improving medication adherence and
may be cost-effective. We suggest that targeting patients
who are most likely to benefit, matching the type if psy-
chotherapy to individual patients and careful selection of
treatment goals via outcomes measures is a way to progress
the field. We also recommend that computerised CBT is
evaluated given its high acceptability and low cost.
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